Context Therapeutics (NASDAQ:CNTX) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Context Therapeutics (NASDAQ:CNTX) to a strong-buy rating in a report published on Monday,Zacks.com reports. Lifesci Capital also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.55) EPS.

Several other brokerages have also recently issued reports on CNTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. JonesTrading assumed coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. HC Wainwright increased their price objective on shares of Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, November 6th. Finally, Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 16th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Trading Down 2.0%

Shares of NASDAQ CNTX opened at $2.43 on Monday. The stock has a market cap of $223.27 million, a P/E ratio of -10.13 and a beta of 1.94. The business’s fifty day simple moving average is $1.86 and its 200-day simple moving average is $1.33. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.85.

Institutional Trading of Context Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at about $3,824,000. Marshall Wace LLP lifted its stake in Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after buying an additional 2,557,448 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after buying an additional 188,202 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after acquiring an additional 134,449 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Context Therapeutics during the third quarter worth approximately $100,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics News Roundup

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded CNTX to a “Strong-Buy” and published detailed quarterly and full-year EPS forecasts (showing expected losses through FY2026), signaling institutional conviction and raising visibility among growth/biotech investors. MarketBeat: Lifesci Capital Research on CNTX
• Neutral Sentiment: Short-interest data for February appears inconsistent (reporting 0 shares and NaN change vs. prior period), which is likely a reporting/data error — this creates ambiguity about whether bearish short activity is increasing or not and can contribute to volatile intraday moves. (No external link provided)
• Neutral Sentiment: Background technicals: CNTX remains volatile with a 12‑month trading range well below its recent high and lighter-than-average volume today, meaning headlines and analyst notes can have outsized impact until volume normalizes. Zacks: Context Therapeutics Coverage

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.